341 related articles for article (PubMed ID: 29297707)
1. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Tannir N; Hammers H; Amin A
Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Hirsch L; Flippot R; Escudier B; Albiges L
Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
[TBL] [Abstract][Full Text] [Related]
3. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
Stitzlein L; Rao P; Dudley R
Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
[TBL] [Abstract][Full Text] [Related]
4. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
6. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
7. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?
Bex A; Etto T; Vyth-Dreese F; Blank C; Griffioen AW
Curr Oncol Rep; 2012 Jun; 14(3):230-9. PubMed ID: 22362358
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
9. New agents and new targets for renal cell carcinoma.
Philips GK; Atkins MB
Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
[TBL] [Abstract][Full Text] [Related]
10. Treatment of renal cell carcinoma: Current status and future directions.
Barata PC; Rini BI
CA Cancer J Clin; 2017 Nov; 67(6):507-524. PubMed ID: 28961310
[TBL] [Abstract][Full Text] [Related]
11. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
Agarwala SS; Case S
Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
[TBL] [Abstract][Full Text] [Related]
12. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
13. Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy.
Barragan-Carrillo R; Govindarajan A; Rock A; Sperandio RC; Pal SK
Hematol Oncol Clin North Am; 2023 Oct; 37(5):965-976. PubMed ID: 37353376
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
16. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
17. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
18. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
